oral administration of 1,4-aryl-2-mercaptoimidazole

  • oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. Jung EJ(1), Hur M, Kim YL, Lee GH, Kim J, Kim I, Lee M, Han HK, Kim MS, Hwang S, Kim S, Woo AM, Yoon Y, Park HJ, Won J.

  • oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model Eun Joo Jung, Minkyu Hur, Young Lim Kim, Ge Hyeong Lee, Jeongmin Kim, Ikyon Kim , Min Woo Lee, Ho Kyun Han, Mi Soon Kim, Sejin Hwang, Sungjoo Kim, A. Mi Woo, Yeup Yoon

  • oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral Administration of 1,4-Aryl-2-mercaptoimidazole Inhibits

    Oral Administration of 1,4-Aryl-2-mercaptoimidazole Inhibits T-Cell Proliferation and Reduces Clinical Severity in the Murine Experimental Autoimmune Encephalomyelitis Model Eun Joo Jung , Minkyu Hur , Young Lim Kim , Ge Hyeong Lee , Jeongmin Kim , Ikyon Kim , MinWoo Lee , Ho-Kyun Han , Mi-Soon Kim , Sejin Hwang , Sungjoo Kim , A. Mi Woo , Yeup

  • oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral Administration of 1,4-Aryl-2-mercaptoimidazole Inhibits

    Request PDF | Oral Administration of 1,4-Aryl-2-mercaptoimidazole Inhibits T-Cell Proliferation and Reduces Clinical Severity in the Murine Experimental Autoimmune Encephalomyelitis Model | T

  • oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. Authors: Eun Joo Jung Minkyu Hur Young Lim Kim Ge Hyeong Lee Jeongmin Kim Ikyon Kim Minwoo Lee Ho-Kyun Han Mi-Soon Kim Sejin Hwang Sungjoo Kim A Mi Woo Yeup Yoon Heon Jin

  • oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits

    Europe PMC is an archive of life sciences journal literature. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severit y in the murine experimental autoimmune encephalomyelitis model.

  • rituximab therapy reduces organ-specific t cell responses

    Rituximab therapy reduces organ-specific T cell responses

    Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. Jung EJ, Hur M, Kim YL, Lee GH, Kim J, Kim I, Lee M, Han HK, Kim MS, Hwang S, Kim S, Woo AM, Yoon Y, Park HJ, Won J

  • novel inhibitors of the calcineurin/nfatc hub - alternatives

    Novel inhibitors of the calcineurin/NFATc hub - alternatives

    Jung EJ, Hur M, Kim YL, Lee GH, Kim J, Kim I, Lee M, Han HK, Kim MS, Hwang S, et al. Oral administration of 1, 4-aryl-2-mercaptoimidazole (KRM-III) inhibits T cell proliferation and reduces clinical severity in murine experimental autoimmune encephalomyelitis model.